CeriBell (NASDAQ:CBLL) Shares Up 9.7% – Still a Buy?

CeriBell, Inc. (NASDAQ:CBLL) shares were up 9.7% on Wednesday . The company traded as high as $23.37 and last traded at $23.37. 335,512 shares changed hands during mid-day trading, a decline of 2% from the average daily volume of 341,043 shares. The stock had previously closed at $21.31.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CBLL shares. BTIG Research reissued a “buy” rating and set a $28.00 target price on shares of CeriBell in a research note on Tuesday. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Finally, Canaccord Genuity Group upped their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.00.

CeriBell Trading Down 0.3%

The stock has a market cap of $889.18 million, a PE ratio of -13.16 and a beta of 0.81. The business’s fifty day moving average is $18.83 and its 200 day moving average is $19.08. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 43.02%. As a group, analysts predict that CeriBell, Inc. will post -1.89 earnings per share for the current year.

Insider Activity

In other news, CTO Raymond Woo sold 1,966 shares of CeriBell stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $35,388.00. Following the completion of the transaction, the chief technology officer owned 195,682 shares of the company’s stock, valued at $3,522,276. The trade was a 0.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph Michael Taylor sold 5,500 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00. Following the completion of the sale, the director directly owned 61,573 shares in the company, valued at approximately $1,133,558.93. The trade was a 8.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 300,685 shares of company stock valued at $5,935,326 in the last 90 days. Insiders own 17.70% of the company’s stock.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in shares of CeriBell during the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd grew its holdings in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the third quarter worth $33,000. CWM LLC increased its position in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.